Bildkälla: Stockfoto

Lipigon Q3 2024: First Patient Recruited - Redeye

Redeye comments on Lipigon’s third quarter report 2024. The same day as the report was released, the company communicated the enrolment of the first patient in the ongoing phase II study of Lipisense.

Redeye comments on Lipigon’s third quarter report 2024. The same day as the report was released, the company communicated the enrolment of the first patient in the ongoing phase II study of Lipisense.
Börsvärldens nyhetsbrev
ANNONSER